Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2023-09-15 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Enhertu recommended in EU for HER2-mutant NSCLC
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated 15 September 2023. It announces a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding the recommendation for approval of the drug Enhertu in the EU for a specific cancer indication, citing trial results (DESTINY-Lung02). The text is structured as a formal press release or regulatory announcement, not a comprehensive financial report (like 10-K or IR) or a transcript. The presence of the RNS header and the nature of the announcement (drug approval news) strongly suggest this is a general regulatory disclosure. Since it is a specific, material announcement that doesn't fit the definitions for ER (Earnings Release), DIV (Dividend), or CAP (Financing), the most appropriate general category for a material, non-financial regulatory update distributed via RNS is 'Regulatory Filings' (RNS). It is not an announcement of a report publication (RPA) because it contains the substantive news itself.
2023-09-15 English
FASENRA PHASE III EGPA TRIAL MET PRIMARY ENDPOINT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about the positive results of the Phase III MANDARA trial for the drug Fasenra in treating eosinophilic granulomatosis with polyangiitis (EGPA). The document includes clinical trial details, drug information, and company background. It is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about clinical trial results, which is typical content for a Form 6-K. The document is substantive and not merely an announcement or certification. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-09-11 English
Fasenra Phase III EGPA trial met primary endpoint
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 0599M' and includes a date stamp from 'RNS, the news service of the London Stock Exchange.' The content is a press release announcing positive clinical trial results (MANDARA Phase III trial for Fasenra in EGPA) and includes quotes from the Principal Investigator and AstraZeneca executives. This format—a brief, timely announcement of material information distributed via the Regulatory News Service (RNS)—is characteristic of a general regulatory announcement that doesn't fit a more specific financial report category like 10-K, ER, or IR. Since it is a regulatory announcement that doesn't fit other specific categories (like DIV, DIRS, or MANG), the most appropriate fallback is Regulatory Filings (RNS). The document length (13,422 chars) is substantial, but its primary function is dissemination via the RNS system.
2023-09-11 English
UPDATE ON US REVIEW OF ULTOMIRIS FOR NMOSD
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides an update on the US regulatory review of Ultomiris for NMOSD, including details about the FDA's complete response letter and clinical trial information. The document does not contain comprehensive financial statements or detailed financial performance data typical of an annual or interim report. It is a regulatory update on a specific product's regulatory status and clinical trial results. The document length is 11,855 characters, which is substantive but the content is focused on regulatory and clinical update rather than financial results or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-09-06 English
Update on US review of Ultomiris for NMOSD
Legal Proceedings Report Classification · 99% confidence The document is identified by the header 'RNS Number : 5427L' and contains a date stamp '06 September 2023'. The content details an update regarding a regulatory review by the US FDA concerning a drug (Ultomiris) and the issuance of a Complete Response Letter (CRL). This type of announcement, which communicates a specific, time-sensitive regulatory or corporate event via the RNS system (London Stock Exchange's news service), fits best under the general 'Regulatory Filings' category, as it is not a comprehensive financial report (10-K, IR), an earnings release (ER), or a specific management/board change (MANG). Since it is a direct, non-financial regulatory update distributed via RNS, RNS is the most appropriate classification.
2023-09-06 English
TOTAL VOTING RIGHTS
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the total voting rights as of 31 August 2023, providing the number of issued shares and voting rights. It references the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. The document is short (3171 characters) and primarily serves as a notification of voting rights rather than a full report or detailed financial disclosure. It does not contain financial statements or detailed analysis, nor is it a shareholder meeting presentation or voting result announcement. Given the nature of the content and the form type (6-K), this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-09-01 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.